Clinical Study

Cdx3379-04- A Phase 2, Mutlicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Cdx-3379 In Combination With Cetuximab In Patients With Advanced Head And Neck Squamous Cell Carcinoma

Posted Date: Oct 1, 2019

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to estimate the ORR for the combination of CDX-3379 in combination with cetuximab in patients with cetuximab-resistant advanced HNSCC


To Be Eligible: >18 Years Or Older, Life Expectancy >12 Weeks, Diagnosed With Hnscc, No Prior Malignancy Within 3 Years, Nonpregnant/Nonbreastfeeding


Head And Neck Cancer, Hnscc

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.